A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab (Q46543444)

23 December 2017

title

A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab (English)

1 reference

23 December 2017

5

M Untch

1 reference

23 December 2017

S Rueckert

1

1 reference

23 December 2017

I Ruehl

series ordinal

2

1 reference

23 December 2017

S Kahlert

series ordinal

3

1 reference

23 December 2017

G Konecny

series ordinal

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

23 December 2017

Expert Opinion on Biological Therapy

published in

1 reference

23 December 2017

volume

5

1 reference

23 December 2017

page(s)

853-866

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.6.853

21 January 2018

Identifiers

DOI

10.1517/14712598.5.6.853

1 reference

23 December 2017

PubMed ID

15952915

1 reference

23 December 2017